Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Vir...
May 12 2021 - 10:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced an abstract presentation related to
AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas
(IBCL) at the European Hematology Association (EHA) Virtual
Congress to be held June 9-17, 2021.
Title: Early safety and efficacy
findings of AUTO1 (CAT19), a fast-off rate CD19 CAR, in
Relapsed/Refractory Indolent B Cell Lymphomas
Presenter: Clare Roddie, MD,
PhD, FRCPath, Consultant Haematologist and Honorary Senior
Lecturer, Cancer Institute, University College London
(UCL)
Date and Time: All e-poster
presentations will be made available on the on-demand Virtual
Congress platform as of Friday, June 11 at 9.00 AM CEST.
As of the data cut-off date of February 18,
2021, 10 r/r IBCL patients had received AUTO1 and nine patients
were evaluable. AUTO1 demonstrated a tolerable safety profile
in adult patients with r/r low grade B-cell lymphoma despite high
disease burden. Early data shows 100% complete remission rates and
excellent CAR engraftment and expansion. Grade 1 CRS was reported
in 4 patients and Grade 2 CRS in 1 patient. No Immune effector
cell-associated neurotoxicity syndrome (ICANS) was observed on
study. At a median of 3.1 months (range 1-5.6m), 8/9 patients are
in ongoing remission. One patient died in complete remission at
month 5.6 of COVID-19.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
About AUTO1 AUTO1 is a
CD19 CAR T cell investigational therapy designed to overcome the
limitations in clinical activity and safety compared to current
CD19 CAR T cell therapies. Designed to have a fast target
binding off-rate to minimize excessive activation of the programmed
T cells, AUTO1 may reduce toxicity and be less prone to T cell
exhaustion, which could enhance persistence and improve the ability
of the programmed T cells to engage in serial killing of target
cancer cells. In collaboration with our academic partner, UCL,
AUTO1 is currently being evaluated in a Phase 1 clinical trial in
adult ALL and B-NHL. The company has also progressed AUTO1 to the
FELIX study, a potential pivotal study.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as "may," "will," "could," "expects,"
"plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding the future clinical
development, efficacy, safety and therapeutic potential of AUTO1,
including progress, expectations as to the reporting of data,
conduct and timing and potential future clinical activity and
milestones; expectations regarding the initiation, design and
reporting of data from clinical trials. Any forward-looking
statements are based on management's current views and assumptions
and involve risks and uncertainties that could cause actual
results, performance, or events to differ materially from those
expressed or implied in such statements. These risks and
uncertainties include, but are not limited to, the risks that
Autolus’ preclinical or clinical programs do not advance or result
in approved products on a timely or cost effective basis or at all;
the results of early clinical trials are not always being
predictive of future results; the cost, timing and results of
clinical trials; that many product candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic
on Autolus’ business. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Autolus’ actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 4, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in
Autolus' subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Autolus undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required by
law.
Contact:
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024